Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about BMRN
Recent news which mentions BMRN
< Previous
1
2
3
4
5
6
7
8
Next >
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
August 24, 2022
Tickers
BMRN
Tags
Biotech
General
EC Approval
From
Benzinga
What's Next in Pfizer's M&A Ramp-Up?
August 20, 2022
Tickers
ALNY
BMRN
BMY
PFE
Tags
PFE
Market News
BMRN
From
Motley Fool
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
August 09, 2022
Tickers
BMRN
Tags
Market News
BMRN
Movers
From
Benzinga
Expert Ratings for Biomarin Pharmaceutical
August 04, 2022
Tickers
BMRN
Tags
BMRN
Market News
Analyst Ratings
From
Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
August 04, 2022
Tickers
BMRN
Tags
Earnings
Health Care
Large Cap
From
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Tickers
ALNY
AMRN
ARQT
BMRN
Tags
Financing
Large Cap
HZNP
From
Benzinga
These eight health-care stocks can keep you invested in the market with less worry
August 02, 2022
Tickers
BIIB
BMRN
BMY
MEDP
Tags
SPX
XLV
BIIB
From
MarketWatch
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Tickers
AFMD
BMRN
CRSP
EXEL
Tags
BMRN
Market News
IONS
From
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Tickers
ABEV
ALNY
ANET
ATRA
Tags
SWIM
Upgrades
LYFT
From
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
July 13, 2022
Tickers
BMRN
Tags
Market News
BMRN
Analyst Ratings
From
Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Tickers
APLS
ATHA
BMRN
CBIO
Tags
PRTK
ATHA
Financing
From
Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 13, 2022
Tickers
BMRN
Tags
BZI/AAR
Benzinga
Market News
From
Benzinga
Is Now the Time to Buy This Risky Stock With Huge Upside Potential?
June 04, 2022
Tickers
BMRN
CPRX
Tags
Recent Press Releases
Market News
BMRN
From
Motley Fool
9 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2022
Tickers
ALGN
BCRX
BMRN
BMY
Tags
BMRN
Market News
ALGN
From
Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
May 09, 2022
Tickers
ADMA
ALT
BHC
BMRN
Tags
Mid Cap
IBB
ALT
From
Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
April 28, 2022
Tickers
AMGN
BMRN
Tags
Health Care
Earnings
Large Cap
From
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Tickers
ACHV
ALKS
ALLO
AMGN
Tags
ACHV
Biotech
Small Cap
From
Benzinga
Biomarin Pharmaceutical Earnings Preview
April 26, 2022
Tickers
BMRN
Tags
Benzinga
Earnings
BMRN
From
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
April 25, 2022
Tickers
A
ABR
AGNC
ALNY
Tags
ABR
Analyst Ratings
CDNA
From
Benzinga
10 Biggest Price Target Changes For Monday
April 25, 2022
Tickers
AMAT
AVY
BMRN
CRL
Tags
Price Target
CRM
AMAT
From
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Tickers
ABBV
ALKS
ALNY
AMGN
Tags
REGN
NURO
BSX
From
Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
April 21, 2022
Tickers
BMRN
Tags
Trading Ideas
Benzinga
BZI/CROSS
From
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Tickers
ALNY
AMGN
AZN
BIIB
Tags
CRSP
LLY
MRTX
From
InvestorPlace
Why BioMarin Pharmaceutical Tumbled on Thursday
February 24, 2022
Tickers
BMRN
Tags
BMRN
Market News
Recent Press Releases
From
Motley Fool
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Tickers
ABCL
ADGI
AGIO
ARYD
Tags
ABCL
GTHX
ICUI
From
Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
Tickers
BMRN
SNY
Tags
SNY
Benzinga
Biotech
From
Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
February 23, 2022
Tickers
BMRN
Tags
Market News
BMRN
BZI/Recaps
From
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Tickers
AKBA
ARNA
AVNS
BHC
Tags
Penny Stocks
GBT
NVRO
From
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Tickers
ABCL
AGIO
ARNA
ATXI
Tags
YMAB
NUVA
IOVA
From
Benzinga
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
February 18, 2022
Tickers
BMRN
Tags
gene therapy
Health Care
BMRN
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.